Scenic Biotech Appoints CMO for SC6177 Clinical Transition

Evidence Company disclosure · Discovery September 10, 2026 · Importance 3/5 · Direction Neutral Summary Scenic Biotech appointed Judith Walker, M.D., as chief medical officer as SC6177 advances through IND-enabling work toward a planned first-in-human study in early 2027. Ann Barbier, M.D., Ph.D., who served…